GPT and Hypoalbuminemia: Ground-glass opacity of the lungs during treatment with MET-TKI (tepotinib) has been reported, which resolves spontaneously with drug discontinuation.[17] Savolitinib is a MET-TKI launched in 2021, and common adverse reactions are peripheral edema, nausea, elevated alanine transaminase, elevated aspartate transaminase, vomiting, hypoalbuminemia, and decreased appetite.